相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

作为潜在的抗凝 agent剂的OleoPectin结构的DFT和动态模拟

Mona T M Ghanem¹, Heba D Hassanein², Ahmed F El-Sayed^3,4,5

¹Chemistry of Medicinal Plant Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Giza, Egypt.

Scientific reports

|June 20, 2025

概括

这项研究探讨了点如何增强oleuropein的特性,改善其吸收并减少副作用. 结合的欧素-丁分子显示出作为一种P2Y12抑制剂用于抗血栓治疗的前景.

科学领域:

计算化学和分子建模.
药理学和药物发现
生物物理和受体相互作用.

背景情况:

欧蛋白表现出有价值的药理性质,但其生物可用性较差,胃肠道副作用较大.
一种多糖类的pectin正在研究其改善oleuropein物理化学和药理特性的潜力.
了解分子相互作用对于开发有效的治疗剂至关重要.

研究的目的:

通过计算建模和评估oleuropein和pectin之间的相互作用.
为了评估一个结合的欧素-pectin分子作为P2Y12受体抑制剂的潜力.
为了研究这种新型分子复合物的抗血栓潜力.

主要方法:

量子化学计算 (半经验和DFT) 用于分子优化和属性分析.
量化结构-活动关系 (QSAR) 描述器计算以评估水友性.
在P2Y12受体上进行分子对接,分子动力学 (MD) 模拟和主要成分分析 (PCA).

主要成果:

DFT的计算证实了oleuropein-pectin结构的稳定性和反应性,而pectin增强了水友性 (Log p-1.171).
双联体2-Oleu(OH) -Pec(OH) 与单个成分相比,对P2Y12受体表现出更高的结合亲和力 (-6.80 kcal/mol) 和稳定性.
MD模拟和PCA验证了2-Oleu(OH) -Pec(OH) 复合物的特殊稳定性和最小的构造变异性.

结论:

pectin显著改善了oleuropein的物理化学特性,这表明生物可用性得到了增强.
新的2-Oleu(OH) -Pec(OH) 复合体显示出强大的P2Y12抑制活性和稳定性.
这种oleuropein-pectin协同作用对开发新型抗血栓治疗具有重大前景.

关键词:

抗凝剂是一种抗凝剂.动态模拟的动态模拟更多关于MESP的地图这是一种欧蛋白.在QSAR中使用QSAR.

更多相关视频

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...